替比夫定、阿德福韦酯联用与恩替卡韦单药治疗失代偿期乙肝肝硬化疗效对比观察

发布时间：2018-05-19 06:08

本文选题：替比夫定 + 阿德福韦酯　；参考：《人人健康》2017年24期

【摘要】：目的:探讨分析采用替比夫定、阿德福韦酯联用与恩替卡韦单药治疗失代偿期乙肝肝硬化的临床疗效。方法:选取2015年2月-2017年1月在我院治疗失代偿期乙肝肝硬化的患者80例,随机将其分为对照组实验组。对照组实施恩替卡韦单药治疗,实验组将替比夫定和阿德福韦酯相互联合进行治疗,对两组患者的治疗效果进行比较。结果:经过治疗后,实验组患者的TBIL、ALB、ALT含量以及PTA和对照组进行比较,没有显著差异,而且经过8周治疗、16周、32周时,实验组的HBV-DNA的转阴率和对照组比较,差异没有统计学意义(P0.05)。结论:对于失代偿期乙肝肝硬化的患者采用替比夫定、阿德福韦酯联用的治疗效果和恩替卡韦单药治疗的效果疗效相当,而且临床效果都比较良好。
[Abstract]:Objective: To explore the clinical efficacy of telbivudine, adefovir combined with entecavir in the treatment of decompensated hepatitis B cirrhosis. Methods: 80 patients in the treatment of decompensated hepatitis B cirrhosis in our hospital in January, February 2015 -2017, were randomly divided into the control group. The control group was treated with entecavir single drug treatment, The experimental group combined the treatment of telbivudine and adefovir in the treatment of two groups of patients. Results: after treatment, the TBIL, ALB, ALT content and PTA in the experimental group were compared, and there was no significant difference between the experimental group and the control group. After 8 weeks treatment, 16 weeks, and 32 weeks, the negative rate of HBV-DNA in the experimental group and the pair were the same. The difference was not statistically significant (P0.05). Conclusion: for patients with decompensated hepatitis B cirrhosis, patients with hepatitis B cirrhosis were treated with telbivudine, and the therapeutic effect of adefovir combined with entecavir was equivalent to the effect of entecavir single drug treatment, and the clinical effect was good.
【作者单位】：淮安市淮安医院;
【分类号】：R512.62;R575.2

【参考文献】